Indivior has impressed with its first notable news since it spun out of Reckitt Benckiser late last year. The specialty pharma company reported that its schizophrenia drug RBP-7000 met the primary endpoint in a Phase III trial, moving it a step closer to its goal of winning FDA approval in 2017.
The fact that this flu season's vaccines were not very effective was bad news for people hoping to avoid the condition but great news for the U.K.'s Reckitt Benckiser Group, which racked up an impressive first quarter on sales of over-the-counter flu meds like Mucinex.
Getting too much of the pain reliever acetaminophen can be a serious issue, particularly for people with liver damage, and so U.K.-based Reckitt Benckiser thinks it best to recall 1.5 million bottles of Mucinex in the U.S. whose back labels don't match the front.
The back labels of some bottles of Mucinex cold medicines may not show they contain acetaminophen and other active ingredients, leading U.K.-based Reckitt Benckiser to recall of 135 lots of the popular product in the U.S.
Flying solo isn't always easy, as recent Reckitt Benckiser spinoff Indivior is learning firsthand. The drugmaker reported an 8% decline in 2014 revenues--and the pain won't end there.
It's new year, new company for Reckitt Benckiser's pharma unit, spun off into Indivior last week. And while 2015 might not be the easiest for the newly minted drugmaker, CEO Shaun Thaxter says investors have much to look forward to a little further down the line.
As shareholders gear up to vote on Reckitt Benckiser's plan to spin off its ailing pharma division, company execs are gearing up to double down on consumer health. And though a handful of pharma heavyweights are targeting the field with renewed focus, the British OTC giant believes it has the edge.
Reckitt Benckiser announced over the summer that it would spin off its pharma unit to shed some extra weight. Now, the British consumer goods company is moving forward with its slimdown regimen, planning to list the addiction control-focused unit on the London Stock exchange before the end of the year.
How many people out there feel like they can relate to an animated green blob, Mr. Mucus, who lives inside patients' chests? Well, Reckitt Benckiser is going to try to make it a little easier for you.
What's that about Bart Becht's shadow? Don't ask Reckitt Benckiser CEO Rakesh Kapoor. He's not living in it.